Lead author Christina Chambers outlines the findings of an investigation into the effects of biologic therapy in pregnant women with rheumatoid arthritis on the risk for opportunistic infections in the babies.
07-11-2017 | ACR/ARHP 2017 | Video
Browse topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings
Conferences